Royal Bank of Canada’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Royal Bank of Canada’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-800	Closed	-$64K	–	7121
2025 Q4	$64K	Hold	800	–	–	﹤0.01%	5419
2025 Q3	$48K	Buy	+800	New	+$43K	﹤0.01%	5833
2025 Q2	–	Sell	-40	Closed	-$2K	–	7028
2025 Q1	$2K	Buy	+40	New	+$2.14K	﹤0.01%	6549
2024 Q1	–	Sell	-100	Closed	-$6K	–	7016
2023 Q4	$6K	Buy	+100	New	+$4.69K	﹤0.01%	6608
2021 Q1	–	Sell	-200	Closed	-$17K	–	7418
2020 Q4	$17K	Hold	200	–	–	﹤0.01%	6128
2020 Q3	$14K	Buy	+200	New	+$14.2K	﹤0.01%	5814
2019 Q3	–	Sell	-800	Closed	-$41K	–	6698
2019 Q2	$41K	Buy	+800	New	+$39.8K	﹤0.01%	5372
2016 Q1	–	Sell	-180	Closed	-$13K	–	6346
2015 Q4	$13K	Buy	180 +110	+157%	+$7.35K	﹤0.01%	5873
2015 Q3	$4K	Buy	+70	New	+$5.97K	﹤0.01%	6211
2015 Q1	–	Sell	-200	Closed	-$13K	–	6128
2014 Q4	$13K	Sell	200 -200	-50%	-$11.7K	﹤0.01%	5524
2014 Q3	$21K	Buy	+400	New	+$19.4K	﹤0.01%	5269

Other funds holding BIB

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

KFS

Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return

CAG

Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Royal Bank of Canada's BIB Position: Q1 2026 in Review

Royal Bank of Canada sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2026, closing a stake of 800 shares — an estimated $64K sold.

Royal Bank of Canada first reported a position in BIB in Q3 2014 and held it in 11 quarters. The position peaked at $64K in Q4 2025. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

Royal Bank of Canada reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2026 after selling out during the quarter.
Royal Bank of Canada sold 800 ProShares Ultra NASDAQ Biotechnology shares in Q1 2026, an estimated $64K.
Royal Bank of Canada first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2014 and held it in 11 quarters.
Royal Bank of Canada's ProShares Ultra NASDAQ Biotechnology position peaked at $64K in Q4 2025.
23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.